Have outcomes of incisional hernia repair improved with time? A population-based analysis.
David R Flum, Karen Horvath, Thomas Koepsell
https://pubmed.ncbi.nlm.nih.gov/12496540/Actively Recruiting
Led by AbSolutions Med Inc. · Updated on 2022-12-27
30
Participants Needed
2
Research Sites
13 weeks
Total Duration
Researchers are evaluating the REBUILD Bioabsorbable device to assess its safety and performance in patients undergoing open, elective, intent-to-cure laparotomy procedures for cancer treatment. This prospective, non-randomized, multi-center study aims to generate descriptive data on how REBUILD distributes suture tension in abdominal wall closures in oncology patients. The study focuses on device-related adverse events and the integrity of the abdominal wall over one year. Participants will have their abdominal wall closed using the REBUILD Bioabsorbable device combined with a surgeons choice of suture during their standard oncologic laparotomy procedure. The study is single-arm, meaning all participants receive the same investigational device without comparison to other treatments. The devices performance will be monitored over a 12-month period after surgery. During the study, participants will be followed up to assess safety and effectiveness. The primary safety outcome is the occurrence of device-related adverse events within 12 months. The primary performance outcome is evaluated through clinical abdominal examinations and, if available, CT scans within 12 months to confirm the abdominal walls integrity. Participants are expected to comply with follow-up visits and study requirements for the full duration of the study.
CONDITIONS
Abdominal Wall Closure After Laparotomy in Oncologic Surgery
D
Daniel Jacobs, MD
K
Kathryn Kelley, BSN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AbSolutions Med Inc.
Lead Sponsor
Cogent Technologies Corporation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants undergo their standard oncologic laparotomy surgery in which the abdominal wall is closed using the REBUILD Bioabsorbable device and suture.
Follow-up visits for up to 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
David R Flum, Karen Horvath, Thomas Koepsell
https://pubmed.ncbi.nlm.nih.gov/12496540/A V Pollock, M Evans
https://pubmed.ncbi.nlm.nih.gov/2804595/M J Playforth, P D Sauven, M Evans...
https://pubmed.ncbi.nlm.nih.gov/3954314/C San Miguel, D Melero, E Jiménez...
https://pubmed.ncbi.nlm.nih.gov/30288617/P M Bevis, R A J Windhaber, P A Lear...
https://pubmed.ncbi.nlm.nih.gov/20603858/Zarko Rasić, Dragan Schwarz, Visnja Nesek Adam...
https://pubmed.ncbi.nlm.nih.gov/21755716/Miguel Ángel García-Ureña, Javier López-Monclús, Luis Alberto Blázquez Hernando...
https://pubmed.ncbi.nlm.nih.gov/25575254/D Alastair Taylor, Steven L Merten, Gavin D Sandercoe...
https://pubmed.ncbi.nlm.nih.gov/29481394/Filip E Muysoms, Olivier Detry, Tijl Vierendeels...
https://pubmed.ncbi.nlm.nih.gov/26943336/Ikemefuna Onyekwelu, Ramakanth Yakkanti, Lauren Protzer...
https://pubmed.ncbi.nlm.nih.gov/30211353/AbSolutions Med Inc.
Lead Sponsor
Cogent Technologies Corporation
Collaborating Sponsor